← The Wire
VNDANasdaq
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations · DE · CIK 1347178
Develops and commercializes innovative therapies for unmet medical needs using genetics and genomics
red 8-K · 90d
$353M
Market cap
$6.14
Last close
+2.2%
1D
+2.3%
5D
874K
Volume
Price · last 39 sessions-18.8%
May 4L $5.73 · H $7.56Jun 29
408
Total filings
Jun 5, 2026
Last filing
12/31
Fiscal year end
DEF 14ADEF 14AApr 23, 2026DEF 14ADEF 14AApr 25, 2025DEF 14APROXY STATEMENTApr 29, 2024DEF 14ADEF 14AApr 24, 2023DEF 14ADEF 14AApr 25, 2022DEF 14ADEF 14AApr 22, 2021DEF 14ADEF 14AApr 22, 2020DEF 14ADEF 14AApr 25, 2019DEF 14ADEF 14AApr 27, 2018DEF 14ADEF 14AApr 27, 2017DEF 14ADEF 14AApr 28, 2016DEF 14ADEF 14AApr 29, 2015DEF 14ADEFINITIVE PROXY STATEMENTApr 7, 2014DEF 14ADEF 14AApr 26, 2013DEF 14ADEF 14AApr 30, 2012DEF 14ADEF 14AApr 29, 2011DEF 14ADEF 14AApr 28, 2010DEF 14ADEF 14AJul 13, 2009
Insider Activity
In the 90 days to Mar 2, 2026: 6 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Polymeropoulos Mihael HristosPresident and CEO | Sell | 156,235 | $8.17 | $1.3M |
| Mar 2, 2026 | Moran Kevin PatrickSVP, CFO & Treasurer | Sell | 42,442 | $8.27 | $351K |
| Mar 2, 2026 | Williams TimothySVP & General Counsel | Sell | 42,434 | $8.27 | $351K |
| Mar 2, 2026 | Birznieks GuntherSVP, Business Development | Sell | 42,431 | $8.27 | $351K |
| Mar 2, 2026 | Wijkstrom JoakimSVP, Chief Marketing Officer | Sell | 30,800 | $8.27 | $255K |
| Feb 23, 2026 | Honore TageDirector | Sell | 30,000 | $8.03 | $241K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance